Published in J Urol on February 01, 2005
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) (2014) 1.04
Recent advances in intravesical drug/gene delivery. Mol Pharm (2006) 0.97
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol (2016) 0.93
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol (2010) 0.87
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis. Oncotarget (2016) 0.77
Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer. Urol Case Rep (2017) 0.75
Bacille-Calmette-Guerin non-responders: how to manage. Transl Androl Urol (2015) 0.75
Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity. Urol Ann (2013) 0.75
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol (2009) 2.71
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol (2002) 2.63
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
Impact of the learning curve on perioperative outcomes in patients who underwent robotic partial nephrectomy for parenchymal renal tumours. Eur Urol (2010) 2.21
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
Management of stage T1 tumors of the bladder: International Consensus Panel. Urology (2005) 1.81
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol (2011) 1.62
Robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of 184 cases. Eur Urol (2007) 1.58
Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP). BJU Int (2013) 1.51
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology (2005) 1.40
An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? Eur Urol (2009) 1.37
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology (2008) 1.19
The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis (2004) 1.18
Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur Urol (2009) 1.09
Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer (2004) 1.05
How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol (2011) 1.03
Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol (2004) 0.96
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Total intracorporeal robot-assisted laparoscopic ileal conduit (Bricker) urinary diversion: technique and outcomes. Can J Urol (2011) 0.93
Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. Urology (2011) 0.93
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol (2012) 0.90
Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch (2002) 0.86
Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy Consortium. Urology (2010) 0.86
Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol (2013) 0.86
Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev (2012) 0.84
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int (2007) 0.83
Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? Eur Urol (2007) 0.83
Case report: pure robot-assisted psoas hitch ureteral reimplantation for distal-ureteral stenosis. J Endourol (2007) 0.81
Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res (2003) 0.80
Surgery illustrated--Surgical Atlas. Robotic radical cystectomy in the male. BJU Int (2009) 0.80
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol (2004) 0.80
The future of urology. Eur Urol (2011) 0.79
Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int (2011) 0.79
A decision aid for GPs for the treatment of elderly male patients with lower urinary tract symptoms (LUTS). Fam Pract (2006) 0.77
The use of intravesical chemotherapy and possibilities for improving its efficacy. Eur Urol (2006) 0.77
The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial. Br J Gen Pract (2006) 0.76
Reply from authors re: Urs E. Studer, Laurence Collette. Robot-assisted cystectomy: does it meet expectations? Eur Urol 2010;58:203-4. Eur Urol (2010) 0.75
High surgical volume, high quality, and low costs: a perfect combination. Is it always possible in patients who need radical prostatectomy? Eur Urol (2006) 0.75
Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int (2011) 0.75
Editorial comment on: P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 0.75
Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non-muscle-invasive transitional cell carcinoma of the bladder: new insights. Eur Urol (2012) 0.75
Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol (2011) 0.75
Female robotic radical cystectomy. BJU Int (2009) 0.75
NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved? Urol Clin North Am (2013) 0.75
5A prospective survey of current prostate biopsy practices among oncological urologists. Can J Urol (2010) 0.75